DynamiCure is a research company based in Waltham, Massachusetts, founded in 2020. They are focused on translating new insights on immuno-normalization into a pipeline of innovative antibody candidates. Their goal is to address significant unmet medical needs in oncology and autoimmune diseases. Their products, such as DC-6001 and DCSZ11, show promise for anti-tumor activity. DynamiCure is dedicated to advancing patient care and providing access to new therapeutics worldwide.